Assessment, pathophysiology and treatment of fatigue in multiple sclerosis

References

• Krupp LB, Pollina DA. Measurement and management of fatigue in progressive neurological disorders. Curl: Opin. Neural 9, 456–460 (1996).
   Google Scholar
• Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Azrh. Phys. Med Rehabil 65,135–138 (1984).
   Google Scholar
• Krupp LB, Alvarez LA, La Rocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch. Neural. 45,435–437 (1988).
   PubMed Web of Science ®Google Scholar
• Vercoluen JHMM, Swanink CMA, Fennis JFM eta]. Dimensional assessment of chronic fatigue syndrome. I P9rhosom. Res. 38, 383–392 (1994).
   Google Scholar
• Vickrey BG, Shatin D, Wolf SM eta]. Management of multiple sclerosis across managed care and fee-for-service systems. Neurology55, 1341–1349 (2000).
   Google Scholar
• Fisk JD, Pontefract A, Ritvo PG et al The impact of fatigue in patient with multiple sclerosis. Can. J. Neural. Sci.21,9–14 (1994).
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Coulthard Morris L, Zeng Q. Psychosocial correlates of fatigue in multiple sclerosis. Arch. Phys. Med. Rehabil 77(2), 165–170 (1996).
   Google Scholar
• Bergamaschi R, Romani V, Versino M etal Clinical aspects of fatigue in multiple sclerosis. Funct. Neural. 12,247–251 (1997).
   PubMed Web of Science ®Google Scholar
• Krupp LB, La Rocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Airh. Neural. 46, 1121–1123 (1989).
   Google Scholar
• Geisser B. Multiple sclerosis: current concepts in management. (Review). Drugs 29, 88–95 (1985). itMurray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can. J. Neural. Sci 12, 251–254 (1985).
   Google Scholar
• Elza BL, Henke CJ, Yelin EH eta]. Correlates of fatigue in older women with rheumatoid arthritis. NUTS. Res. 42,93–99 (1993).
   Google Scholar
• Vercoulen JH, Hommes OR, Swanink CM etal The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Anil. Neural. 53(7), 642–649 (1996).
   Google Scholar
• Krupp LB, Coyle PK, Doscher C et al Fatigue therapy in multiple sclerosis: results of a double-blind randomized parallel trial of amantadine, pemoline and placebo. Neurology 45, 1956–1961 (1995). Class I study comparing the effects of arnantadine, pemoline and placebo.
   Google Scholar
• Cookfair DL, Fischer J, Rudick R et al Fatigue severity in low disability MS patients participating in a Phase III trial of Avonex for relapsing remitting multiple sclerosis. Neurology 48,173a (1997).
   PubMed Web of Science ®Google Scholar
• Bigland-Ritchie B, Jones DA, Hosking GP etal Central and peripheral fatigue in sustained maximum voluntary contraction of human quadriceps muscle. Clin. Sci. Mal Med. 54, 609–614 (1978).
   PubMedGoogle Scholar
• Edwards RIIT Human muscle function and fatigue. In: Human Muscle Fatigue: Physiological Mechanisms CIBA Foundation Symposium #82. Pittam Medical, London, UK, 1–18 (1981).
   Google Scholar
• Djaidetti R, Ziv I, Achiron A, Melamed E. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative assessment. Neurology 46,632–635 (1996).
   PubMedGoogle Scholar
• Schwid SR, Thornton CA, Pandya S eta]. Quantitative assessment of motor fatigue and strength in MS. Neurology53,743 (1999).
   Google Scholar
• Krupp LB, Elkins LE. Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology55,934-939 (2000). Main neuropsychological evidence for 'mental fatigue' in MS patients.
   Google Scholar
• Guthrie TC, Nelson DA. Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J. Neural. Sci. 129, 1–8 (1995).
   PubMed Web of Science ®Google Scholar
• Bohr KC, Haas J. Sleep related breathing disorders do not explain daytime fatigue in multiple sclerosis. Multiple Sclemsis 4,289a (1998).
   Google Scholar
• Miller RG, Green AT, Moussavi RS eta]. Excessive muscular fatigue in patients with spastic paraparesis. Neurology40, 1271–1274 (1990).
   Google Scholar
• Lenman A, Tulley FM, Vrbova G etal Muscle fatigue in some neurological disorders. Muscle and Nerve12,938–942 (1989).
   PubMed Web of Science ®Google Scholar
• Kent-Braun JA, Sharma KR, Weiner MW, Miller RG. Effects of exercise on muscle activation and metabolism in multiple sclerosis. Muscle and Nerve 17,1162–1169 (1994).
   Google Scholar
• Sheean GL, Murray NMF, Rothwell JC, Miller DH, Thompson AJ. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 120,299–315 (1997).
   Google Scholar
• •Provides neurophysiological evidence that fatigue in MS may be due to central abnormalities.
   Google Scholar
• Rice CL, Vollmer TL, Bigland-Ritchie B. Neuromuscular responses of patients with multiple sclerosis. Muscle and Nerve 15, 1123–1132 (1992).
   Google Scholar
• Sandroni P, Walker C, Starr A. Fatigue in patients with multiple sclerosis. Motor pathway conduction and event-related potentials. Airh. Neural. 49,517–524 (1992).
   Google Scholar
• ••One of the first suggestions that fatigue inMS may be related to central motor abnormalities involving motor programming independently from corticospinal involvement.
   Google Scholar
• Colombo B, Martinelli Boneschi F eta]. MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. Neural 247,506–509 (2000).
   Google Scholar
• Brasil-Neto JP, Cohen LG, Hallett M. Central fatigue as revealed by postexercise decrement of motor evoked potentials. Muscle and Nerve 17,713–719 (1994).
   Google Scholar
• Galardi L, Madema S, Amadio S eta]. Assessment of central fatigue by transcranial magnetic stimulation in multiple sclerosis patients. In: 'European activities on surface electromyography, Proceedings of the 1st SENIAM workshop', Torino, Italy, Hermes HJ, Merletti R, Freriks B (eds), 127–129 (1996).
   Google Scholar
• Gandevia SC, Allen GM, Butler GE, Taylor JL. Supraspinal factors in human muscle fatigue: evidence for suboptimal output from the motor cortex. J. Physiol 490, 529–536 (1996).
   PubMed Web of Science ®Google Scholar
• Lloyd AR, Gandevia SC, Hales JR Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with the chronic fatigue syndrome. Brain 114,85–98 (1991).
   PubMed Web of Science ®Google Scholar
• Roelcke U, Kappos L, Lechner-Scott J et al Reduced glucose matabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue. Neurology48, 1566–1571 (1997).
   PubMed Web of Science ®Google Scholar
• Leocani L, Colombo B, Magnani G eta]. Fatigue in multiple sclerosis is associated with abnormal cortical activation to voluntary movement — EEG evidence. Neuroimage 13,1186–1192 (2001).
   Google Scholar
• Filippi M, Rocca MA, Colombo B etal. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 15,559–567 (2002).
   Google Scholar
• Codella M, Rocca MA, Colombo B, Martinelli-Boneschi F, Comi G, Filippi M. Cerebral grey matter pathology and fatigue in patients with multiple sclerosis: a preliminary study. I Neural. Sc]. 194,71-74 (2002).
   Google Scholar
• Bertolone K, Coyle PK, Krupp LB et al Cytokine correlates of fatigue in multiple sclerosis. Neurology43, A356 (1993).
   Web of Science ®Google Scholar
• Chao CC, DeLa Hunt M, Hu S eta]. Immunologically mediated fatigue: a murine model. Clin. Immunopath. 64, 161–165 (1992).
   Google Scholar
• Gottberg K, Gardulf A, Fredrikson S. Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side effects. NIult. Scler 6,349–354 (2000).
   Google Scholar
• Mainero C, Faroni J, Gasperini C et al Fatigue and magnetic resonance imaging activity in multiple sclerosis. I Neural. 246(6), 454–458 (1999).
   Google Scholar
• Giovannoni G, Thompson AJ, Miller DH, Thompson EJ. Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology57, 676–681 (2001).
   PubMed Web of Science ®Google Scholar
• Krupp LB. Treatment of fatigue in multiple sclerosis. In:Multiple Sclemsis therapeutics. Rudick A, Goodkin E (Eds), Martin Dunitz, 467–474 (1999).
   Google Scholar
• Heilman KM, Watson RE Fatigue. Neurology Net. Gamin. 1,283–287 (1997).
   Google Scholar
• Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RVV. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann. Neural. 39, 432–441 (1996).
   PubMed Web of Science ®Google Scholar
• •Randomized, controlled, simple blind study on exercise therapy in MS-related fatigue.
   Google Scholar
• Di Fabio RP, Sodeberg, Choi T et al Extended out-patient rehabilitation: its influence on symptom frequency, fatigue and functional status for persons with progressive multiple sclerosis. Airh. Phys. Med. Rehabil 79,141–146 (1998).
   PubMed Web of Science ®Google Scholar
• Deale AM, Chalder T, Marks I, Wessely S. Cognitive behaviour therapy for chronic fatigue syndrome: a randomized controlled trial. Am. PTchiatry54, 408–414 (1997).
   Google Scholar
• Butler S, Chalder T, Ron M, Wessely S. Cognitive behaviour therapy in CFS. Nemo'. Neurosurg. Psychiatry 54,153–158 (1991).
   PubMed Web of Science ®Google Scholar
• Beenakker EA, Oparina TT, Hartgring A, Teelken A, Ar4unyan AV, De Keyser J. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology57(5), 892–894 (2001).
   Google Scholar
• •Only randomized, placebo-controlled study on cooling therapy in MS-related fatigue.
   Google Scholar
• Capello E, Gardella M, Leandri M et al Lowering body temperature with a cooling suit as symptomatic treatment for thermosensitive multiple sclerosis patients. Ital. Nemo'. Sci. 16,533–539 (1995).
   PubMedGoogle Scholar
• Flensner G, Lindencrona C. The cooling- suit: case studies of its influence on fatigue among eight individuals with multiple sclerosis. Adv. NUTS. 37,541–550 (2002).
   Google Scholar
• White AT, Wilson TE, Davis SL, Petajan JH. Effect of precooling on physical performance in multiple sclerosis. Mutt. Stier 6,176–180 (2000).
   PubMed Web of Science ®Google Scholar
• Wade AJ, Broadhead MW, Cady EB, Llewelyn ME, Tong HN, Newham DJ. Influence of muscle temperature during fatiguing work with the first dorsal interosseous muscle in man: a 31P-NMR spectroscopy study. Eur. I Appl Physiol 81, 203–209 (2000).
   Google Scholar
• De Ruiter CJ, De Haan A. Similar effects of cooling and fatigue on eccentric and concentric force—velocity relationships in human muscle. I Appl. Physiol 90,2109–2116 (2001).
   PubMed Web of Science ®Google Scholar
• Oksa J, Ducharme MB, Rintamaki H. Combined effect of repetitive work and cold on muscle function and fatigue. Appl. Physiol 92,354–361 (2002).
   Google Scholar
• Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9,69–92 (1999).
   PubMed Web of Science ®Google Scholar
• Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neural. 46,676–680 (1989).
   PubMed Web of Science ®Google Scholar
• Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can.j Neural. Sc]. 14,273–278 (1987).
   PubMed Web of Science ®Google Scholar
• •First class I study comparing the effects of amantadine, pemoline and placebo.
   Google Scholar
• Rosenblum D, Saffir M. Therapeutic and symptomatic treatment of multiple sclerosis. Phys. Med. Rehabil Clin. N Am. 9, 587–601 (1998).
   PubMedGoogle Scholar
• Kurtzke JE Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neumlogy33, 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. PTchosom. Res. 37, 753–762 (1993).
   Google Scholar
• Rosenberg GA, Appenzeller 0. Amantadine, fatigue and multiple sclerosis. Atrh. Neural. 45, 1104–1106 (1988).
   Google Scholar
• Sailer M, Heinze HJ, Schoenfeld MA, Hauser U, Smid HG. Amantadine influences cognitive processing in patients with multiple sclerosis. Pharmacopsychiatry 33, 28–37 (2000).
   Google Scholar
• Geisler MW Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Atrh. Neural. 53, 185–188 (1996).
   Google Scholar
• Wheinshenker BG, Penman M, Bass B. A double-blind randomized crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 42, 1468–1471 (1992).
   Google Scholar
• Carter JL, Stevens JC, Smith B etal A double-blind, placebo-controlled crossover trial of 3,4-dyaminopyridine in the symptomatic treatment of multiple sclerosis. Ann. Neural. 34, 272–273 (1993).
   Google Scholar
• Bever CT Jr, Anderson PA, Leslie J et al Treatment with oral 3,4-diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47, 1457–1462 (1996).
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertelsmann FW, de Waal R etal. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Atrh. Neural. 51, 1136–1139 (1994).
   Google Scholar
• Polman CH, Bertelsmann FVV, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch. Neural. 51, 292–296 (1994).
   Google Scholar
• Sheean G, Murray N, Rotwell J etal An open label clinical and electrophysiological study of 3,4-diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 121, 967–975 (1998).
   PubMed Web of Science ®Google Scholar
• Rossini PM, Pasqualetti P, Pozzilli C etal. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mutt. Scler 7, 354–358 (2001). Specifically evaluates the effects of aminopyridine on fatigue in progressive MS.
   Google Scholar
• Van Diemen HAM, Polman CH, von Dangen JMMM eta]. The effects of 4-aminopyridine on clinical signs in multiple sclerosis: a randomised, placebo-controlled, double-blind crossover study. Ann. Neural. 32, 123–130 (1992).
   Google Scholar
• Bever CT Jr, Young D, Anderson PA eta]. The effects of 4-arninopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44, 1054–1059 (1994).
   Google Scholar
• Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann. Neural. 27, 186–192 (1990).
   Google Scholar
• Broughton RJ, Fleming JA, George CF et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neumlogy 49, 444–451 (1997).
   PubMed Web of Science ®Google Scholar
• Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med. 1, 109–116 (2000).
   Google Scholar
• Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre Phase 2 study. Neural. Neurosurg. Psychiaby 72, 179–183 (2002). First randomized, placebo-controlled, single-blind study on modafinil in the treatment of MS-related fatigue.
   Google Scholar
• Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14, 540–545 (1991).
   PubMed Web of Science ®Google Scholar
• Wingerchuck DM, Benarroch EE, O'Brien PC et al. Aspirin for multiple sclerosis-related fatigue: results of a double-blind, placebo-controlled study. Neurology 58\(Suppl. 3), A492—A493 (2002).
   Google Scholar